| Name | Title | Contact Details |
|---|---|---|
Matthew DiBella |
General Counsel | Profile |
Latonya Izzard |
Chief Compliance Officer and Director of Operations | Profile |
Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy.
Were one of the world’s leading providers of high quality, empty, hard capsules serving global pharmaceutical and dietary supplement markets.
Presutti Laboratories is a Rolling Meadows, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology.
Elixir, (formerly EnvisionRxOptions) a wholly owned subsidiary of Rite Aid, is a pharmacy benefits and services company with the unique ability to optimize the full pharmacy care experience.